The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders-Reference-Cited by-同舟云学术

The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders

Published:2019-03 Issue: Volume:180 Page:43-52
ISSN:0014-4835
Container-title:Experimental Eye Research
language:en
Short-container-title:Experimental Eye Research

Author:

Hu Tjing-Tjing^ORCID,Vanhove Marc,Porcu Michaël,Van Hove Inge^ORCID,Van Bergen Tine,Jonckx Bart^ORCID,Barbeaux Philippe,Vermassen Elke,Feyen Jean H.M.

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Reference72 articles.

1. Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes;Abu El-Asrar;Clin. Exp. Ophthalmol.,2010

2. Ocular distribution and pharmacodynamics of SF0166, a topically administered alphavbeta3 integrin antagonist, for the treatment of retinal diseases;Askew;J. Pharmacol. Exp. Therapeut.,2018

3. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity;Bhowmick;J. Biol. Chem.,2001

4. Causes of vision loss worldwide, 1990-2010: a systematic analysis;Bourne;Lancet Glob Health,2013

5. The pathobiology of diabetic complications: a unifying mechanism;Brownlee;Diabetes,2005

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetic retinopathy from the vitreous proteome perspective: The INS^C94Y transgenic pig model study;PROTEOMICS;2024-08-09

2. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration;Archives of Pharmacal Research;2024-06

3. Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment;Journal of Peptide Science;2024-02-21

4. Diabetic eye disease: novel therapeutic strategies;Chronic Complications of Diabetes Mellitus;2024

5. AN INTEGRIN RENAISSANCE: RECENT PROGRESS OF INTEGRIN MODULATORS IN THE CLINIC;Medicinal Chemistry Reviews;2023-11-16